Keros Therapeutics, Inc.
KROS
$14.57
$0.412.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 148.45M | -46.03M | -52.96M | -45.26M | -43.11M |
| Total Depreciation and Amortization | 344.00K | 332.00K | 314.00K | 306.00K | 277.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.45M | 9.77M | 9.38M | 9.13M | 8.41M |
| Change in Net Operating Assets | 2.93M | -10.09M | 12.76M | -3.98M | -10.13M |
| Cash from Operations | 161.17M | -46.01M | -30.50M | -39.80M | -44.56M |
| Capital Expenditure | -565.00K | -289.00K | -386.00K | -310.00K | -946.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -565.00K | -289.00K | -386.00K | -310.00K | -946.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.00K | 75.54M | 156.07M | 3.60M | 157.06M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -130.00K | -65.00K | -259.00K |
| Cash from Financing | 4.00K | 75.54M | 155.94M | 3.53M | 156.80M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 160.61M | 29.25M | 125.06M | -36.58M | 111.30M |